Sparganii

Sparganii (Sparganium stoloniferum) contains bioactive lignans and phenylpropanoids that exert anticancer effects primarily by activating intrinsic apoptotic pathways via caspase-3 and caspase-9. Preclinical research highlights its potential to overcome gefitinib resistance in lung adenocarcinoma and suppress tumor cell migration.

Origin & History

Sparganii Rhizoma, known as Sparganium rhizome, is the dried tuber of Sparganium stoloniferum, a perennial aquatic herb native to traditional Chinese medicine. It is typically harvested in autumn, sliced, and sun-dried for use in various decoction and extraction methods.

Historical & Cultural Context

Traditionally, Sparganii Rhizoma is used in Chinese medicine for gynecological issues such as dysmenorrhea and abdominal masses. It is combined with Curcumae Rhizoma for treating tumors and blood stasis, with its use documented in classical TCM texts.

Health Benefits

• Inhibits proliferation of gefitinib-resistant lung adenocarcinoma cells, evidenced by in vitro studies. • Promotes apoptosis in cancer cells via caspase-3/9 activation, as shown in preclinical research. • Reduces migration of cancer cells, supporting potential anti-metastatic effects in vitro. • Downregulates p-AKT1 and p-mTOR, pathways involved in prostate cancer, according to cell studies. • Enhances mitochondrial-mediated apoptosis in resistant cancer cell lines, demonstrated in network pharmacology studies.

How It Works

Sparganii's bioactive lignans and phenylpropanoids trigger the intrinsic mitochondrial apoptosis pathway by upregulating pro-apoptotic proteins such as Bax and downregulating Bcl-2, ultimately activating caspase-9 and downstream executioner caspase-3. These compounds also appear to suppress EGFR-related downstream signaling, offering a mechanism to overcome acquired gefitinib resistance in NSCLC cells. Additionally, inhibition of matrix metalloproteinases (MMPs) and interference with epithelial-to-mesenchymal transition (EMT) markers may underlie the observed reduction in cancer cell migration.

Scientific Research

There are no human clinical trials or meta-analyses available for Sparganii Rhizoma. The current evidence is limited to preclinical studies, including network pharmacology and in vitro experiments.

Clinical Summary

Current evidence for Sparganii is derived almost entirely from in vitro cell-line studies, including experiments on gefitinib-resistant lung adenocarcinoma (PC-9/GR cells), with no peer-reviewed randomized controlled trials in humans published to date. In vitro models have demonstrated measurable reductions in cell viability and migration at defined extract concentrations, and apoptosis rates were quantified via flow cytometry and caspase activity assays. Animal (rodent) xenograft models have provided preliminary support for tumor growth suppression, but sample sizes are small and study designs vary considerably. The overall evidence strength is low; human pharmacokinetic, safety, and efficacy data are lacking, and clinical translation remains speculative.

Nutritional Profile

Sparganii (Sparganium stoloniferum, San Leng rhizome) is a medicinal herb used in Traditional Chinese Medicine, not typically consumed as a food source, so conventional macronutrient profiling is limited. Known compositional data includes: Bioactive compounds: Phenylpropanoids including ferulic acid (reported at approximately 0.1–0.5 mg/g dry weight), p-coumaric acid, and caffeic acid derivatives. Flavonoids: naringenin and kaempferol glycosides present in trace amounts (<0.1 mg/g). Terpenoids: sesquiterpene lactones and diterpenoids identified as key bioactive constituents, though precise concentrations vary by extraction method. Sterols: beta-sitosterol and stigmasterol detected in lipid fractions. Polysaccharides: crude polysaccharide content estimated at 5–15% of dry weight, contributing to immunomodulatory effects. Organic acids: succinic acid and oxalic acid present in small quantities. Minerals: moderate potassium content reported; trace amounts of calcium, magnesium, and iron consistent with rhizome-class botanicals, though specific mg/g values lack standardized published data. Crude fiber: estimated 10–20% of dry weight as insoluble fiber from rhizome cell wall material. Protein: approximately 3–8% of dry weight, low biological value. Bioavailability note: Active phenylpropanoids show improved bioavailability with alcohol-based extraction versus aqueous; polysaccharide fractions are poorly absorbed systemically but may exert local gut effects.

Preparation & Dosage

There are no clinically studied dosage ranges for Sparganii Rhizoma in humans. In vitro studies utilized freeze-dried powder at concentrations of 1-8 mg/mL for 24-72 hours. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumae Rhizoma, formononetin, beta-sitosterol, bisdemethoxycurcumin, stigmasterol

Safety & Interactions

No formal human safety or toxicology trials for isolated Sparganii lignans have been published, making it impossible to define a safe or effective clinical dose at this time. Traditional Chinese medicine preparations containing Sparganium stoloniferum are contraindicated in pregnancy due to reported emmenagogue and uterotonic activity, which poses a risk of miscarriage. Potential interactions with anticoagulant drugs (e.g., warfarin) are theoretically plausible given traditional uses involving blood-moving properties, and concurrent use should be avoided until interaction data exist. Individuals with bleeding disorders, those scheduled for surgery, or patients on EGFR-targeted therapies should consult a healthcare provider before use.